[A19-09] Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 01.08.2019
Project no.:
A19-09
Commission:
Commission awarded on 24.01.2019 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adults with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease
Clear advantages in symptomatic progression, disadvantages in some side effects; indication of considerable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A20-36 | Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-20 | Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A19-51 | Apalutamide (prostate cancer) - Addendum to Commission A19-09 | Commission completed |
Federal Joint Committee (G-BA)
2019-08-01 A G-BA decision was published.